CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01663766
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:32.033341+00:00
Published At: 2021-08-19T00:00:00+00:00
Record Updated At: 2021-08-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["GVHD (Acute or Chronic)", "Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)", "Myelodysplastic Syndrome", "Chronic Myelogenous Leukemia (CML)", "Multiple Myeloma (MM)", "Non-Hodgekin Lymphoma (NHL-both Follicular \u0026 Diffuse Large Cell)", "Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-08-19"
protocolSection.identificationModule.nctId: "NCT01663766"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.